EuroEyes International Eye Clinic Limited (HK:1846)
:1846
Want to see HK:1846 full AI Analyst Report?
Top Page
EuroEyes International Eye Clinic Limited
(1846)
Select Model
Select Model
Rating:65Neutral
Price Target:
HK$3.00
▲(0.00% Upside)
Action:Reiterated
Date:05/04/26
The score is driven primarily by solid underlying financial stability and cash generation, offset by a meaningful recent decline in profitability/ROE and higher debt. Technicals are mildly negative, while the low P/E and dividend yield provide valuation support.
Positive Factors
Stable cash generation
Consistently positive operating cash flow and a recovery in free cash flow provide durable internal funding for clinic upkeep, selective expansion, and dividends. Strong cash conversion reduces reliance on capital markets and supports operational resilience through cycles in elective healthcare demand.
Negative Factors
Profitability decline
Earnings fell materially while revenue rose, indicating margin compression from higher costs, pricing mix shifts, or operational inefficiencies. Sustained weaker profitability would erode reinvestment capacity and reduce the durability of cash returns to shareholders absent structural margin improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable cash generation
Consistently positive operating cash flow and a recovery in free cash flow provide durable internal funding for clinic upkeep, selective expansion, and dividends. Strong cash conversion reduces reliance on capital markets and supports operational resilience through cycles in elective healthcare demand.
Read all positive factors
EuroEyes International Eye Clinic Limited (1846) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$869.78M
Dividend Yield1.99%
Average Volume (3M)156.72K
Price to Earnings (P/E)17.9
Beta (1Y)0.18
Revenue Growth11.23%
EPS Growth-31.73%
CountryHK
Employees322
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.17
Shares Outstanding320,706,000
10 Day Avg. Volume164,000
30 Day Avg. Volume156,720
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)0.78
Price to Sales (P/S)1.22
P/FCF Ratio6.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EuroEyes International Eye Clinic Limited Business Overview & Revenue Model
Company Description
EuroEyes International Eye Clinic Limited provides vision correction services in Germany, Denmark, and the People's Republic of China. The company offers refractive laser surgery, which include ReLEx SMILE and FemtoLASIK; phakic lens (ICL) surgery...
How the Company Makes Money
EuroEyes makes money primarily by charging patients for medical eye-care services and elective vision-correction procedures delivered through its clinics. Key revenue streams typically include: (1) procedure fees for refractive surgeries (e.g., la...
EuroEyes International Eye Clinic Limited Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
74
Positive
Cash Flow
71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 796.04M | 715.68M | 714.29M | 610.29M | 632.93M |
| Gross Profit | 324.33M | 286.59M | 335.52M | 270.84M | 312.55M |
| EBITDA | 163.64M | 141.89M | 292.10M | 220.44M | 278.80M |
| Net Income | 54.45M | 82.28M | 131.24M | 89.47M | 133.56M |
Balance Sheet | |||||
| Total Assets | 1.95B | 1.60B | 1.75B | 1.54B | 1.37B |
| Cash, Cash Equivalents and Short-Term Investments | 696.70M | 653.23M | 720.38M | 779.57M | 861.58M |
| Total Debt | 410.19M | 319.29M | 384.26M | 290.41M | 221.48M |
| Total Liabilities | 667.78M | 473.72M | 588.09M | 497.95M | 328.55M |
| Stockholders Equity | 1.25B | 1.09B | 1.13B | 1.01B | 1.01B |
Cash Flow | |||||
| Free Cash Flow | 148.11M | 117.41M | 102.30M | 152.46M | 228.71M |
| Operating Cash Flow | 193.75M | 197.75M | 191.85M | 208.76M | 273.26M |
| Investing Cash Flow | -113.47M | -83.83M | -180.28M | -131.81M | -59.90M |
| Financing Cash Flow | -115.97M | -136.82M | -102.76M | -102.22M | -69.18M |
EuroEyes International Eye Clinic Limited Technical Analysis
Negative
3.00
Price Trends
2.75
Negative
2.85
Negative
3.01
Negative
Market Momentum
>-0.01
Positive
46.53
Neutral
8.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1846, the sentiment is Negative. The current price of 3 is above the 20-day moving average (MA) of 2.74, above the 50-day MA of 2.75, and below the 200-day MA of 3.01, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.53 is Neutral, neither overbought nor oversold. The STOCH value of 8.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1846.
EuroEyes International Eye Clinic Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$1.84B | 9.50 | 7.66% | 9.29% | -3.21% | -6.77% | |
74 Outperform | HK$376.45M | 4.98 | 4.28% | 7.10% | -2.78% | -24.77% | |
65 Neutral | HK$869.78M | 17.86 | 4.33% | 1.99% | 11.23% | -31.73% | |
64 Neutral | HK$1.39B | 20.66 | 5.64% | 1.20% | 1.75% | ― | |
56 Neutral | HK$476.77M | 15.01 | 27.04% | ― | 2.00% | ― | |
54 Neutral | HK$1.50B | 256.57 | 0.48% | 0.49% | -2.63% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1846
EuroEyes International Eye Clinic Limited
2.71
-0.23
-7.82%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.66
0.31
13.29%
HK:3309
C-MER Eye Care Holdings Limited
1.11
-0.57
-33.93%
HK:3869
Hospital Corporation of China Ltd
3.43
-2.57
-42.83%
HK:3886
Town Health International Medical Group Ltd.
0.22
>-0.01
-3.93%
HK:0722
UMP Healthcare Holdings Limited
0.47
0.08
21.45%
EuroEyes International Eye Clinic Limited Corporate Events
EuroEyes posts 9% rise in first-quarter 2026 surgery volumes
Apr 30, 2026
EuroEyes International Eye Clinic Limited reported that it performed 7,598 eye surgeries in the first quarter of 2026, according to preliminary unaudited figures. This represents an increase of about 9% from the 6,997 procedures carried out in the...
EuroEyes Updates Name of Cayman Share Registrar Without Operational Change
Apr 28, 2026
EuroEyes International Eye Clinic Limited has announced an administrative change to its corporate infrastructure, renaming its principal share registrar and transfer office in the Cayman Islands from Harneys Fiduciary (Cayman) Limited to Ascentium...
EuroEyes Declares Final Dividend for 2025 Financial Year
Mar 31, 2026
EuroEyes International Eye Clinic Limited has declared a final ordinary cash dividend of HKD 0.0126 per share for the financial year ended 31 December 2025, payable in Hong Kong dollars. The dividend is subject to shareholder approval on 30 June 2...
EuroEyes Moves to Enable Hybrid Meetings With New Corporate Governance Documents
Mar 31, 2026
EuroEyes International Eye Clinic Limited plans to amend its existing memorandum and articles of association and adopt a new version to modernize its corporate governance framework. The proposed changes, which require shareholder approval at the u...
EuroEyes Grows Revenue in 2025 but Profit Drops on Higher Costs
Mar 31, 2026
EuroEyes International Eye Clinic Limited reported an 11.2% increase in revenue to HK$796.0 million for the year ended 31 December 2025, with gross profit up 13.2% to HK$324.3 million. Despite this top-line growth, profit for the year fell 32.9% t...
EuroEyes Sets March 2026 Board Meeting to Approve 2025 Results and Consider Dividend
Mar 16, 2026
EuroEyes International Eye Clinic Limited has scheduled a board meeting for 31 March 2026 to review and approve the group’s annual results for the year ended 31 December 2025 and to approve their release. The board will also consider whether...
EuroEyes to Make Very Substantial Acquisition of FYEO Europe and Resume Trading
Feb 26, 2026
EuroEyes International Eye Clinic Limited has agreed, via its Netherlands subsidiary, to acquire the entire issued share capital of FYEO Europe B.V. from a group of independent vendors, in a transaction classified under Hong Kong listing rules as ...
EuroEyes Halts Trading Ahead of Major Acquisition Announcement
Feb 23, 2026
EuroEyes International Eye Clinic Limited has requested a halt in trading of its shares on the Main Board of the Hong Kong Stock Exchange, effective from 9:00 a.m. on 23 February 2026. The suspension comes as the company prepares to release an ann...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.